PALO ALTO, Calif., July 24, 2019 /PRNewswire/ -- Kodiak
Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical
company specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that data from
the ongoing KSI-301 clinical study will be presented at the
American Society of Retina Specialists (ASRS) 2019 Annual Meeting
being held from July 26 – 30 in
Chicago, IL.
"We remain excited by KSI-301's performance in the clinic and
the strong engagement we are seeing with our investigators. The
data being presented for the first time at ASRS 2019 from our Phase
1b multiple-dose study will address
initial safety and efficacy of KSI-301 in patients with treatment
naïve wet AMD, diabetic macular edema/diabetic retinopathy and
retinal vein occlusion. We look forward to Dr. Dugel sharing the
data for the first time with the retina specialist community from
the podium at ASRS," said Victor
Perlroth, M.D., Kodiak's Chief Executive Officer.
Details of the presentation are as follows:
Oral Presentation: Antibody Biopolymer Conjugates: A
Novel Scientific Approach and Platform for Extended-Durability
Retinal Medicines - First Results from a Phase 1b Proof of Concept Study of KSI-301, an
anti-VEGF ABC
Presenter: Pravin U. Dugel,
M.D. -- Clinical Professor, Department of Ophthalmology, Roski Eye
Institute, Keck School of Medicine, University
of Southern California; Managing Partner, Retinal
Consultants of Arizona, Retinal
Research Institute, Phoenix,
AZ
Session: AMD Neovascular Part II Symposium
Presentation date and time: Saturday,
July 27, 2019 – 11:48am
CDT
The slide presentation will be available on the Kodiak Investor
Relations website at http://ir.kodiak.com/ following
completion of the presentation.
About KSI-301
KSI-301 is an investigational therapy built on the Company's ABC
Platform and is designed to maintain potent and effective drug
levels in ocular tissues for longer than existing agents. Kodiak's
objective with KSI-301 is to improve real-world outcomes for
patients with retinal vascular diseases and to enable earlier
treatment and prevention of vision loss for patients with diabetic
eye disease.
About Kodiak Sciences Inc.
Kodiak™ is a clinical-stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ merges the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration and diabetic eye diseases. Kodiak has
leveraged its ABC Platform to build a pipeline of product
candidates in various stages of development including KSI-501, our
bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases with an inflammatory component. Kodiak
is based in Palo Alto, CA. For
more information, visit www.kodiak.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking
statements are not based on historical fact and include statements
regarding our platform technology and potential therapies, future
development plans, clinical and regulatory objectives and the
timing thereof, anticipated design of planned clinical trials,
expectations regarding the potential efficacy and commercial
potential of our product candidates, including KSI-301, the
anticipated presentation of data, the results of our research and
development efforts and our ability to advance our product
candidates into later stages of development. Forward-looking
statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions, and
include words such as "may," "will," "should," "would," "expect,"
"plan," "believe," "intend," "pursue," and other similar
expressions among others. Any forward-looking statements are based
on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to, the preliminary
safety, efficacy and durability data for our KSI-301 product
candidate from the Phase 1 study will not continue or persist;
cessation or delay of any of the ongoing clinical studies and/or
our development of KSI-301 may occur; future potential regulatory
milestones of KSI-301, including those related to current and
planned clinical studies may be insufficient to support regulatory
submissions or approval; anticipated presentation of data at
upcoming conferences may not occur; our research and development
efforts and our ability to advance our product candidates into
later stages of development may fail; any one or more of our
product candidates may not be successfully developed, approved or
commercialized; adverse conditions in the general domestic and
global economic markets; as well as the other risks identified in
our filings with the Securities and Exchange Commission. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled "Risk Factors" in our most recent Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof and Kodiak undertakes no obligation to update
forward-looking statements, and readers are cautioned not to place
undue reliance on such forward-looking statements.
"Kodiak," "ABC Platform" and the Kodiak logo are registered
trademarks or trademarks of Kodiak Sciences Inc. in various
jurisdictions.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-upcoming-presentation-at-american-society-of-retina-specialists-asrs-2019-annual-meeting-300890072.html
SOURCE Kodiak Sciences Inc.